3933.HK

For the upcoming H1 2026 earnings report (due 2026-08-31), The United Laboratories International Holdings Limited needs to report a Profit attributable to owners of the Company of at least RMB600 million. This would represent a significant positive surprise compared to the company's recent profit warning, which indicated an unaudited net profit of approximately RMB340 million for H1 2026.

Exceeding this lowered guidance signals the profit decline is less severe than feared, restoring investor confidence. It suggests challenges, including reduced Novo Nordisk license fees, are more manageable or temporary, potentially realigning with the bullish GLP-1 investment thesis and boosting valuation.

For the upcoming H1 2026 earnings report (due 2026-08-31), The United Laboratories International Holdings Limited needs to achieve year-over-year growth of at least 15% in Revenue from Finished Products. This would represent a significant rebound from the reported -17.79% decline in the prior period.

Achieving 15% growth in Revenue from Finished Products validates the company's strategic focus and signals a strong rebound, particularly with GLP-1 related offerings. This performance enhances competitive position, boosts investor confidence, and drives a positive rerating consistent with the bullish GLP-1 investment thesis.

For the upcoming H1 2026 earnings report (due 2026-08-31), The United Laboratories International Holdings Limited needs to achieve year-over-year Total Revenue growth of at least 10%. This significantly surpasses current analyst full-year 2026 growth forecasts, which range from 4.9% to 7%. This performance must be accompanied by continued positive updates on the UBT251 GLP-1 drug pipeline, specifically confirming the ongoing progress of Phase 3 clinical trials in China, which initiated in Q3 2026.

Achieving double-digit Total Revenue growth signals a strong turnaround from the 4.0% decline in 2025, validating the bullish GLP-1 investment thesis. Coupled with confirmed progress of UBT251's Phase 3 trials, it demonstrates strong execution in a booming GLP-1 market, enhancing the company's competitive position and driving a positive rerating by investors.